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Abstract
Introduction: High grade B-cell lymphoma and diffuse large B cell 
exhibiting myelocytoma (MYC) translocation with B-cell lymphoma 2 
(BCL2) and/or B-cell lymphoma 6 (BCL6) re-arrangements, also known as 
double and triple hit lymphomas, are aggressive entities. World Health 
Organization update 2017 includes this cytogenetically defined category 
of “High grade B cell lymphoma with myelocytoma MYC and BCL2 and/
or BCL6 rearrangements” as a distinct entity on their own. We present 
an interesting case of an obese patient presenting with a neck mass, 
suspected to be an aggressive thyroid carcinoma, which eventually turned 
out to be a high grade B-cell lymphoma. Case Description: A 64 years-
old male presented with complaints of neck pain for 10 weeks and a 
huge swelling in front of neck for 4 weeks. Respiratory system evaluation 
revealed cough, pleuritic pain and expectoration. Rest of the systemic 
review was unremarkable. Baseline reports showed hypothyroid status. 
Ultrasonography (USG) thyroid showed right upper pole Thyroid Imaging 
Reporting and Data Systems - 4 (TIRADS-4) nodule with bilateral cervical 
lymphadenopathy for which correlation with fine needle aspiration 
cytology (FNAC) was advised. Magnetic resonance imaging (MRI) films 
were submitted for review which showed overall features of locally invasive 
primary thyroid malignancy. Case was discussed in a multi-disciplinary 
team (MDT) meeting and suspicion arose of non-thyroidal origin of 
tumor. Patient underwent Positron emission tomography/computed 
tomography (PET/CT) as per MDT recommendations. PET/CT findings 
were highly suggestive of lymphomatous disease as opposed to thyroidal 
malignancy suspicion early on, which was confirmed on histopathology 
of cervical nodes. Practical Implications: High grade B-cell lymphoma 
is an aggressive entity and can be very deceptive in its presentation, 
as evident from this case report. Functional imaging modalities such as 
Fluorodeoxyglucose (F-18 FDG) PET/CT can provide crucial assistance in 
unmasking a deceptive disease entity masquerading as some other, thus 
changing the management plan completely.
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Introduction
Lymphomas involving the B cells are known as 
B-cell lymphomas. Both Hodgkin’s lymphomas 
and majority of the non-Hodgkin lymphomas 
(NHL) make up the B-cell lymphomas and are 
subdivided into low and high grade. Diffuse large 
B-cell lymphomas are known for their biological 
diversity, more so a subgroup having closeness 
to Burkitt’s lymphoma and a poor prognosis is 
well known. It has been observed by cytogenetic 
evaluation that some patients with rearrangements 
of myelocytoma (MYC) and B-cell lymphoma 2 
BCL2 and/or B-cell lymphoma 6 BCL6 (double/
triple hit lymphomas [DHL] [THL]) increasingly 
require more intensive therapy.[1]
High-grade B-cell lymphomas (HGBLs) and diffuse 
large B-cell lymphoma (DLBCL) demonstrating 
MYC translocation with simultaneous BCL2 
(or BCL6) rearrangements are called DHL and 
THL.[2] The World Health Organization (WHO) 2017 
update also defines this category of ‘HGBL with 
MYC and BCL2 and/or BCL6 rearrangements’ (DHL/
THL) as an entirely different entity.[3]
MYC, BCL2 and/or BCL6 related groups are 
not clearly described in the recent genetic 
classifications, but they are present in two new 
WHO designations as high-grade B-cell lymphoma 
with MYC and BCL2 and/or BCL6 translocation 
and high-grade B-cell lymphoma not otherwise 
specified.[3] Optimum management plan approach 
to this group is difficult which is partly explained 
by the low frequency of groups such as DHL and 
the absence of a clear-cut biologic definition. 
This makes up a diverse category of related 
malignancies whose response and survival on 
standard therapeutic modalities varies quite a lot, 
with worse outcomes in some subtype cases.[3]
Case Description
A 64-year-old male patient presented to the 
hospital with complaints of swelling and pain 
in neck. The swelling started 4 weeks ago, and 
pain presented nearly 6 weeks before the onset 
of swelling. Furthermore, the patient reported 
difficulty in breathing, swallowing and changes 
in voice.
According to the patient, he was in the usual state 
of health approximately 10 weeks ago when he 
started experiencing pain in his neck. Subsequently, 
he developed swelling in the area of pain, which 
progressively increased in size. Swelling was 
associated with shortness of breath, which was 
worse on lying in a supine position. Around the 
same time, he developed hoarseness of voice and 
bilateral subcostal pain with productive whitish 
phlegm without any history of haemoptysis. There 
was no history of fever, nausea or vomiting. The 
patient had a history of 40 pack-year of smoking. 
However, he had quit smoking 2 months before his 
visit to the hospital.
Respiratory system evaluation revealed cough 
with expectoration and pleuritic chest pain. Rest of 
the systemic review was unremarkable. Neck pain 
intensity was given a score of 2 out of possible 10, 
on an 11-point numeric verbal pain rating scale, 
where 0 was indicative of ‘no pain’ and 10 was 
suggestive of ‘worst pain ever,’ by the patient. There 
were no known drug or food allergies. The patient 
was on tablet prednisolone 5 mg 2 times a day, for 
the management of compromised airway.
During the general physical examination, the patient 
was fully conscious, well oriented in time, place and 
person. He had a bilateral neck swelling which was 
stony hard in consistency. The left side cervical 
lymph nodes were palpable. The examination of 
respiratory, cardiovascular, abdominal and central 
nervous systems was unremarkable. Likewise, the 
motor and sensory system evaluation of the upper 
and lower extremities was normal, and all reflexes 
were present and symmetric.
Diagnosis and management
Baseline blood reports of the patient revealed 
that the levels of the thyroid-stimulating 
hormone and the total thyroxine (T4) were low 
(44.8 milli-international units/litre [mIU/L] and 
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2.4 picomole/litre, respectively). These were 
suggestive of hypothyroidism, and the patient 
was started with 50 μg tablet thyroxine, on a daily 
dose of 100 μg, in the morning, 20 min before the 
breakfast.
Before the hospital visit, the patient had a magnetic 
resonance imaging (MRI) scan of the neck. The MRI 
films showed large locally advanced unresectable 
tumour of the left lobe of thyroid gland with local 
extension along with enlarged cervical nodal 
disease. The large lobulated locally advanced 
tumour was involving the left thyroid lobe and 
extended into the left carotid sheath. It completely 
encased the common carotid artery and extended 
to the suprasternal notch. It was inseparable 
from the brachiocephalic vessels. Tumour had a 
significant mass effect on trachea and displaced it 
to the right side of the midline. Tumour was also 
inseparable from proximal cervical oesophagus 
and infiltrated into tracheo-oesophageal recess. No 
extension into the spinal canal was seen. Tumour 
was deemed inseparable from the prevertebral 
muscles. Enlarged cervical nodes were seen in 
bilateral Level II and III, and a lobulated mass was 
observed at the right Level IIa, which measured 
3 cm in maximum dimensions.
In the hospital, as part of initial workup, the patient 
underwent ultrasonography (USG) of thyroid gland 
and a repeat MRI of the neck. The USG showed 
heterogeneous thyroid gland with a right upper 
pole solid hypoechoic thyroid imaging reporting 
and data systems-4 nodule with irregular margins[4] 
[Figure 1]. The gland was associated with extensive 
bilateral cervical lymphadenopathy. The MRI neck 
suggested presence of a locally unresectable 
soft-tissue abnormality in the anterior neck, 
which was involving the left thyroid lobe with 
retrosternal and superior mediastinal extension 
and cervical adenopathy. Overall these features 
were suggestive of locally invasive primary thyroid 
malignancy [Figure 2].
The case was discussed in a multidisciplinary 
team meeting and suspicion arose of non-
thyroidal origin of tumour. The patient was advised 
computed tomography (CT) and positron emission 
tomography/CT study (PET/CT) of neck, chest, 
abdomen and pelvis region and fine-needle 
aspiration (FNA)/tru-cut biopsy of cervical node and 
thyroidal mass. CT of neck, chest, abdomen and 
pelvis region demonstrated neck mass as before 
and right lower segmental pulmonary embolism 
for which enoxaparin was administered.
The PET/CT showed hypermetabolic bulky 
confluent nodal disease above the diaphragm with 
tonsillar, thyroid, oesophageal, anterior chest wall 
and skeletal involvement. There was no evidence 
of nodal disease below the level of diaphragm. 
Figure 1: Ultrasound thyroid axial and sagittal images 
showing right upper pole solid irregular hypoechoic 
thyroid imaging reporting and data systems-4 nodule
Figure  2: Magnetic resonance imaging neck without 
contrast showing a neck mass, supposedly thyroidal in 
origin
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PET/CT findings were highly suggestive of 
lymphomatous disease as opposed to thyroid 
malignancy suspicion early on [Figure 3].
Enlarged hypermetabolic palatine tonsi ls 
had standardised uptake value (SUV) 18.4. 
Fluorodeoxyglucose (FDG) avid cervical and 
supraclavicular adenopathy was noted involving 
all nodal stations with contiguous extension into 
anterior mediastinum to the level of carina. This 
was more on the left side, and it was encasing 
the trachea, neck vessels and the oesophagus, 
which was thickened and avid up to the level of 
carina. Conglomerate dimensions were 19.7 cm 
craniocaudally (CC) with SUV 28 on the left side 
and 16.5 cm CC having SUV 24.1 on the right side. 
Thyroid gland was involved as well. The mass was 
extending anteriorly into anterior chest wall with 
oedema and stranding. Multiple hypermetabolic 
mediastinal nodes were noted in right paratracheal, 
aortopulmonary window and subcarinal regions. 
Hypermetabolic right axillary nodes were seen, the 
largest node measured 3 cm with SUV 27.3 along 
with tiny left retropectoral nodes. FDG avid foci of 
marrow uptake were noted in sternum (SUV 7.5) and 
left 6th costochondral junction (SUV 6) [Figure 4].
An USG-guided core biopsy of the right cervical 
lymph node and FNA of thyroid mass was 
planned. However, only cervical node biopsy was 
completed. The thyroid biopsy was aborted due 
to the possibility of high vascularity of the neck 
mass. The right cervical node histopathology 
report revealed a high-grade B-cell non-Hodgkin’s 
lymphoma with extensive necrosis and crush 
artefact.
Immunohistochemical stains showed positive 
leukocyte common antigen and B lymphocyte 
cluster differentiation (CD20). Proliferation marker 
protein (Ki67) showed a high proliferative index 
of 90%. Cellular myelocytomatosis oncogene 
(C-MYC) was positive in 60% lymphoma cells 
while Bc12 was weakly positive in tumour. Mouse 
monoclonal antibody (Cam 5.2), synaptophysin, 
cluster differentiation (CD3), cluster differentiation 
(CD10), cluster differentiation (CD 5), terminal 
deoxynucleotidyl transferase (TdT) and cluster 
differentiation (CD34) were negative. Fluorescent 
in situ hybridisation (FISH) for C-MYC and B-cell 
lymphoma 2 BCL 2 was also suggested to evaluate 
for double hit type of high-grade B-cell lymphoma, 
but the test could not be performed.
Discussion
Among NHL, DLBCL is the most common and 
the most aggressive type of tumour. DLBCL is 
an inhomogeneous disease at the genetic and 
molecular levels. Gene expression profiling studies 
divide the DLBCL on the basis of cell of origin 
into two major groups; germinal centre B-cell and 
activated B-cell subtypes. However, 15%–20% 
of these approximately do not fit into the above 
Figure  4: Maximal intensity projection image F-18 
fluorodeoxyglucose positron emission tomography/
computed tomography, unmasked the high-grade B-cell 
lymphoma masquerading as thyroid carcinoma
Figure  3: Axial images of F-18 fluorodeoxyglucose 
positron emission tomography/computed tomography, 
unmasked the h igh-grade B-cel l  l ymphoma 
masquerading as thyroid carcinoma
Journal Of Cancer & Allied Specialties 5
Case ReportJ Cancer Allied Spec 2020;6(2):8
two mentioned categories and therefore are 
unclassifiable on a molecular basis.[5]
For the classification of DLBCL based on cells of 
origin, various immunohistochemistry methods 
have been used. Moreover, additionally to the 
cells of origin, prognostic role for MYC and BCL2 
genetic translocations and coexpression of proteins 
have been identified by proteomics and genetic 
studies tests.[3] Studies using FISH have reported 
that 7%–10% of DLBCL have MYC, BLC2 and/or 
BCL6 translocations. These have previously been 
called DHL or THL.[3] The WHO in its recent revision 
of lymphoma classification has recognised high-
grade B-cell lymphoma with rearrangements of 
MYC and BCL2 and/or BCL6, separately.[3]
Repair of genetic/DNA damage, protein synthesis, 
metabolism and reactions to stressors are all closely 
related to MYC, a transcription factor which regulates 
the expression of several target genes involved in 
the cell cycle.[6] Mutations involving promoter/
regulatory regions, chromosomal translocation 
and increase in copy number can lead to activation 
of MYC on chromosome 8 (8q24). MYC activates 
the tumour protein 53 (TP53) pathways in normal 
functioning cells which results in cell apoptosis. 
However, it has been noted that cells having MYC 
translocations can have TP53 inactivating mutations, 
which prevent the process of cell apoptosis.
DLBCL with  MYC translocations can be 
accompanied by BCL2 and/or BCL6 translocations 
and has conferring aggressive clinical behaviour 
secondary to central nervous system involvement. 
Due to these reasons, additional central nervous 
system prophylaxes with aggressive induction 
regimens are recommended.[7]
With this report, we hope to illuminate that FDG PET 
not only compliments other anatomical imaging 
modalities but also further provides invaluable 
information and has the capability of redirecting 
the entire treatment protocol in confusing cases 
as evident in this case.
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